Table 1.
Patient demographic and clinical characteristics.
| Diagnosis | Age | BMI | Smoking | Comorbidities | Date of diagnosis | Date of sampling | Immunotherapy | PACNS specific changes in MRI + MRA | PACNS specific changes in angiography | CNS biopsy |
|---|---|---|---|---|---|---|---|---|---|---|
| PACNS | 20–25 | 19.4 | No | None | May 16 | May 16 | Naive | Yes | Yes | No |
| PACNS | 50–55 | 25.7 | No | Diabetes mellitus type II, arterial hypertension | May 12 | Nov 16 | Yes* | Yes | Yes | Yes |
| PACNS | 45–50 | 30.1 | No | Arterial hypertension | Apr 16 | Apr 16 | Naive | Yes | Yes | No |
| PACNS | 45–50 | 37.9 | No | Diabetes mellitus type II, arterial hypertension | Sep 16 | Mar 15 | Naive | Yes | Yes | No |
| IIH | 25–30 | 34.5 | No | Arterial hypertension | Oct 15 | Oct 15 | No | |||
| IIH | 40–45 | 33.9 | No | None | Nov 15 | Jan 16 | No | |||
| IIH | 40–45 | 35.5 | No | None | May 15 | May 15 | No | |||
| IIH | 75–80 | 31.2 | No | None | Nov 15 | Dec 15 | No |
No significant difference for key clinical features such as age (p = 0.88, Mann-Whitney-U-Test), gender (p = 0.47, Fisher's exact test) or body mass index (p = 0.34, Mann-Whitney-U-Test) were found. PACNS specific changes in MRI/MRA and angiography included blood vessel irregularities such as stenosis and dilatation, infarction and black blood contrast enhanced T1 weighted images showing contrast enhancement in the vessel walls (Figure 1).
Immunotherapy with 16 cycles of cyclophosphamid (750 mg/m2 KOF) June 2012 to Feb 2013 and May 2015 to Nov 2016, methotrexat from Feb 2013 to Oct 2013. CNS, central nervous system; PACNS, primary angiitis of the CNS; BMI, body mass index; MRI, magnetic resonance imaging; MRA, magnetic resonance angiography.